N-pyridin-2-ylmethyl-4-[(5,6,7,8-tetrahydroquinolin-8-ylamino)methyl]benzamide | 405229-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-pyridin-2-ylmethyl-4-[(5,6,7,8-tetrahydroquinolin-8-ylamino)methyl]benzamide
• 英文别名: N-Pyridin-2-ylmethyl-4-[(5,6,7,8-tetrahydro-quinolin-8-ylamino}-methyl]-benzamide；N-(pyridin-2-ylmethyl)-4-[(5,6,7,8-tetrahydroquinolin-8-ylamino)methyl]benzamide
• CAS: 405229-20-1
• 化学式: C₂₃H₂₄N₄O
• 分子量: 372.47
• InChiKey: UMIHNGYTXPGHTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-pyridin-2-ylmethyl-4-[(5,6,7,8-tetrahydroquinolin-8-ylamino)methyl]benzamide 、 2-(氯甲基)-1H-苯并[d]咪唑-1-羧酸叔丁酯 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 以28%的产率得到4-{[(1H-benzo[d]imidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl}-N-(pyridin-2-ylmethyl)benzamide
  参考文献：
  名称：

  Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

  摘要：

  The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure activity relationship (SA R) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-Amethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 (125)I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 mu M. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

  DOI：

  10.1021/jm100073m
• 作为产物：
  描述：

  4-{[(2-Nitrobenzenesulfonyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-N-pyridin-2-ylmethyl-benzamide 在 potassium carbonate 、 苯硫酚 、 水 作用下， 以 乙腈 、 二氯甲烷 为溶剂， 以93%的产率得到N-pyridin-2-ylmethyl-4-[(5,6,7,8-tetrahydroquinolin-8-ylamino)methyl]benzamide
  参考文献：
  名称：

  Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication

  摘要：

  The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure activity relationship (SA R) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-Amethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 (125)I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 mu M. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

  DOI：

  10.1021/jm100073m

文献信息

• Chemokine receptor binding heterocyclic compounds
  申请人：——

  公开号：US20020147192A1

  公开（公告）日：2002-10-10

  Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.

  含有多种杂环取代基的三级胺可用作化学受体调节剂。
• CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
  申请人：Bridger Gary

  公开号：US20080090846A1

  公开（公告）日：2008-04-17

  Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.

  含有多种杂环芳基取代基的三级胺可用作趋化因子受体调节剂。
• US6835731B2
  申请人：——

  公开号：US6835731B2

  公开（公告）日：2004-12-28
• US7312234B2
  申请人：——

  公开号：US7312234B2

  公开（公告）日：2007-12-25
• [EN] CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES SE LIANT AVEC LES RECEPTEURS DE CHIMIOKINES
  申请人：ANORMED INC

  公开号：WO2002022599A2

  公开（公告）日：2002-03-21

  Tertiary amines containing a multiplicity of heteroaromatic substituents are useful as chemokine receptor modulators.